Hepalink Strengthens Biologics Presence With OncoVent JV

China's Shenzhen Hepalink, a public company that claims to be one of the largest makers of heparin in the world, is aiming to build up its R&D activities for biologics through a newly formed Chinese JV with OncoQuest, which will leverage the two companies’ expertise and assets to develop novel cancer immunotherapies.

More from China

More from Focus On Asia